Re: HCV: Most Like to Succeed
>I'm wondering if it will end up morphing into something more unwieldy, such as
"Most likely to succeed, efficacy"
"Most likely to succeed, tolerability"<
By the time HCV drugs get to phase-2b, their ability to stop viral replication is generally well established. Hence, safety and tolerability are the main differentiators between good drug candidates and bad drug candidates during late-stage trials. I think this means we’re in agreement.
Market Data 
Markets 
AI
